- Home
- SGHT vs PROK Comparison
SGHT vs PROK Comparison
Compare SGHT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- PROK
- Stock Information
- Founded
- SGHT 2011
- PROK 2015
- Country
- SGHT United States
- PROK United States
- Employees
- SGHT N/A
- PROK N/A
- Industry
- SGHT Medical Specialities
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGHT Health Care
- PROK Health Care
- Exchange
- SGHT Nasdaq
- PROK Nasdaq
- Market Cap
- SGHT 304.4M
- PROK 220.6M
- IPO Year
- SGHT 2021
- PROK N/A
- Fundamental
- Price
- SGHT $5.43
- PROK $1.74
- Analyst Decision
- SGHT Buy
- PROK Buy
- Analyst Count
- SGHT 6
- PROK 5
- Target Price
- SGHT $7.20
- PROK $4.50
- AVG Volume (30 Days)
- SGHT 147.1K
- PROK 423.0K
- Earning Date
- SGHT 11-07-2024
- PROK 11-12-2024
- Dividend Yield
- SGHT N/A
- PROK N/A
- EPS Growth
- SGHT N/A
- PROK N/A
- EPS
- SGHT N/A
- PROK N/A
- Revenue
- SGHT $79,395,000.00
- PROK N/A
- Revenue This Year
- SGHT $3.39
- PROK N/A
- Revenue Next Year
- SGHT $11.43
- PROK N/A
- P/E Ratio
- SGHT N/A
- PROK N/A
- Revenue Growth
- SGHT N/A
- PROK N/A
- 52 Week Low
- SGHT $1.42
- PROK $1.12
- 52 Week High
- SGHT $8.45
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- SGHT 40.27
- PROK 43.46
- Support Level
- SGHT $5.20
- PROK $1.67
- Resistance Level
- SGHT $5.44
- PROK $1.83
- Average True Range (ATR)
- SGHT 0.28
- PROK 0.13
- MACD
- SGHT -0.02
- PROK 0.01
- Stochastic Oscillator
- SGHT 17.70
- PROK 23.68
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.